China's Sinovac to double annual COVID-19 vaccine capacity to 1 bln doses

2 minute read
Register now for FREE unlimited access to

BEIJING, Jan 13 (Reuters) - A unit of Sinovac Biotech (SVA.O) could double annual production capacity of its CoronaVac COVID-19 vaccine to 1 billion doses by February, the group's chairman said on Wednesday.

More than 7 million doses of CoronaVac vaccine, one of the three China has included in its emergency vaccination programme, have so far been supplied to regions including the city of Beijing and Guangdong province, Sinovac Biotech Chairman Yin Weidong told a news conference.

While the first phase of Sinovac Life Sciences' existing production line can make 500 million CoronaVac doses in one year, another with annual capacity of 500 million doses could become operational by February, Yin said.

Register now for FREE unlimited access to

Researchers in Brazil on Tuesday released new efficacy data for the vaccine, for which there have been varying rates of success from trial sites in three countries. read more

Trials in different countries are designed differently, but the CoronaVac doses being tested came from the same batch, Yin said.

"These Phase III clinical trial results are sufficient to prove that CoronaVac vaccine's safety and effectiveness are good around the world," Yin said.

Register now for FREE unlimited access to
Reporting by Roxanne Liu and Yew Lun Tian Editing by David Goodman

Our Standards: The Thomson Reuters Trust Principles.